- Clinical Trials
- July 2024
- 60 Pages
Global
From €1168EUR$1,250USD£988GBP
- Report
- June 2024
- 200 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- May 2024
- 139 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- January 2022
- 60 Pages
Global
From €3690EUR$3,950USD£3,122GBP
- Report
- January 2022
- 60 Pages
Global
From €3690EUR$3,950USD£3,122GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1868EUR$2,000USD£1,581GBP
Keratoconus is an optical disorder that affects the cornea, causing it to become thin and cone-shaped. This can lead to blurred vision, light sensitivity, and other vision problems. To treat this condition, drugs are used to reduce inflammation, strengthen the cornea, and improve vision. These drugs are known as Keratoconus Drugs.
Keratoconus Drugs are typically administered as eye drops, tablets, or injections. They can be used to reduce inflammation, improve vision, and slow the progression of the disease. Commonly used drugs include corticosteroids, anti-inflammatory drugs, and collagen cross-linking agents.
Keratoconus Drugs are used in the treatment of a variety of optical disorders, including myopia, astigmatism, and presbyopia. They are also used to treat dry eye syndrome, glaucoma, and cataracts.
The Keratoconus Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Allergan, Bausch + Lomb, Novartis, Santen, and Shire. Show Less Read more